Peripheral T Cells Lymphoma (PTCL)
Oncology·MeSH: Lymphoma
Prevalence
56.0 / 100K
Incidence
19.6 / 100K/yr
2 drugs in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| Golcadomide | Merus N.V. (MRUS) |
Phase 1(1)
| Drug | Company |
|---|---|
| roginolisib | Merus N.V. (MRUS) |
Compare drugs
Frequently asked questions
How many drugs are in development for Peripheral T Cells Lymphoma (PTCL)?
BioSniper tracks 2 drugs in development for Peripheral T Cells Lymphoma (PTCL) across 1 company.
How many clinical trials target Peripheral T Cells Lymphoma (PTCL)?
There are 1 clinical trial targeting Peripheral T Cells Lymphoma (PTCL) tracked by BioSniper.
What is the prevalence of Peripheral T Cells Lymphoma (PTCL)?
The estimated prevalence of Peripheral T Cells Lymphoma (PTCL) is approximately 56.0 per 100,000 population.
Deep-dive into Peripheral T Cells Lymphoma (PTCL)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis